Immuno-Oncology | Specialty

Simon Shares Insight on Emerging Immunotherapy Regimens in NSCLC

February 21st 2018

George R. Simon, MD, discusses emerging advancements with immunotherapy combination strategies for patients with NSCLC.

Dr. Sonpavde on Novel Prognostic Marker for Atezolizumab in Bladder Cancer

February 20th 2018

Guru Sonpavde, MD, director of Bladder Cancer at Dana-Farber Cancer Institute, discusses a novel prognostic marker for patients with advanced bladder cancer being treated with the PD-L1 inhibitor atezolizumab (Tecentriq).

Immunotherapy Trials Offer Hope in Advanced Penile Cancer

February 20th 2018

Guru Sonpavde, MD, discusses the importance of clinical trial enrollment for patients with penile cancer.

Dr. Bellmunt on Challenges With Immunotherapy in Bladder Cancer

February 20th 2018

Joaquim Bellmunt, MD, PhD, associate professor of medicine, Harvard Medical School, director, Bladder Cancer Center, Dana-Farber Cancer Institute, discusses challenges with immunotherapy in bladder cancer.

Pembrolizumab Continues to Demonstrate Long-Term Efficacy in Melanoma

February 19th 2018

The PD-1 inhibitor pembrolizumab (Keytruda) continues to be a promising frontline immunotherapy option for patients with advanced melanoma.

Dr. Patel on the FDA Approval of Durvalumab in NSCLC

February 17th 2018

Jyoti D. Patel, MD, professor of medicine, director of thoracic oncology, the University of Chicago Medicine, discusses the FDA approval of durvalumab (Imfinzi) in patients with non

FDA Approves Durvalumab for Locally Advanced NSCLC

February 17th 2018

The FDA has approved durvalumab for the treatment of patients with locally advanced, unresectable stage III non–small cell lung cancer who have not progressed following chemoradiotherapy.

Biomarkers and Novel Approaches in CRC

February 17th 2018

Reverce Study: Outcomes and Impact

February 17th 2018

Sequencing of Therapy in Refractory mCRC

February 17th 2018

Management of Side Effects With TAS-102

February 17th 2018

Proactive Side Effect Management With Regorafenib

February 17th 2018

Clinical Implications of the ReDOS Findings

February 17th 2018

The Regorafenib Dose Optimization Study

February 17th 2018

Treatment Options in Refractory mCRC

February 17th 2018

Treatment Goals in Refractory mCRC

February 17th 2018

Pembrolizumab Plus SBRT Active in Advanced Solid Tumors

February 17th 2018

The addition of pembrolizumab to stereotactic body radiotherapy induced an objective response rate of 13.2% among patients with advanced solid tumors.

Immunotherapy Poised to Move Forward Into Stage III NSCLC

February 16th 2018

A panel of several of the world’s foremost experts on immunotherapy in lung cancer discuss durvalumab and other emerging approaches for stage III NSCLC.

Dr. Sampath on Safety of Immunotherapy Plus Radiation in Lung Cancer

February 15th 2018

Sagus Sampath, MD, assistant professor, Department of Radiation Oncology, City of Hope, discusses the safety profile of immunotherapy in combination with radiation in the treatment of patients with lung cancer.

Pembrolizumab Update Solidifies Survival Benefit in Bladder Cancer

February 15th 2018

Joaquim Bellmunt, MD, PhD, discusses the updated pembrolizumab findings, as well as the future of immunotherapy in bladder cancer.